EASL Congress 2026 - Poster Presentations
May 29, 2026 at 8:30 AM CEST
Session: MASLD: Therapy (TOP-176)
Title: Concurrent Responses in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis Following Pemvidutide Treatment: 24-Week Responder Analyses from the Phase 2b IMPACT Trial
Speaker: Dr. Scot Roberts, Chief Scientific Officer, Altimmune
Session: MASLD: Therapy (FRI-201)
Title: Effect of Pemvidutide on Cardiovascular Risk Factors in Patients with MASH: 48-Week Results from the Phase 2b IMPACT Trial
Speaker: Dr. Shaheen Tomah, Director, Clinical Development, Altimmune
